Digest Network Come funziona
Network
/
Società
Am
Non verificato

Amneal Pharmaceuticals, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaSaluteSanità

30 comunicati stampa

Guarda tutti i comunicati
02/05/2025
Web e Social Network
Telefonia e Varie
Mercato azionario
Biotecnologia
Farmaceutica
Salute
Amneal Reports First Quarter 2025 Financial Results
Fonte
Amneal Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
11/04/2025
Biotecnologia
Igiene alimentare
Associazioni/Professionisti
Sanità
Salute
Farmaceutica
Assicurazioni
Amneal Donates $1.5 Million to Support Patients During Parkinson’s Awareness Month
Fonte
Amneal Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
08/04/2025
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Biotecnologia
Sanità
Farmaceutica
Salute
Amneal to Report First Quarter 2025 Results on May 2, 2025
Fonte
Amneal Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
07/04/2025
Eventi
Industria
Salute
Igiene alimentare
Sanità
Medicina - Varie
Farmaceutica
Biotecnologia
Amneal Announces New Data from Phase 3 Study Showing Significant Improvements in Sleep Quality with CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Parkinson’s Disease
Fonte
Amneal Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
03/04/2025
Mercato del lavoro
Industria
Psichiatria
Salute
Farmaceutica
Amneal Announces Expanded Coverage for CREXONT® (Carbidopa and Levodopa) to Enhance Access for Parkinson’s Disease Patients in the U.S.
Fonte
Amneal Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
01/04/2025
Industria
Biotecnologia
Sanità
Salute
Farmaceutica
Oncologia
Amneal Launches BORUZU™, First Ready-to-Use Bortezomib Injection for Multiple Myeloma and Mantle Cell Lymphoma
Fonte
Amneal Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
10/03/2025
Eventi
Web e Social Network
Biotecnologia
Sanità
Farmaceutica
Salute
Amneal to Participate at Upcoming Investor Conference
Fonte
Amneal Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
03/03/2025
Oncologia
Igiene alimentare
Salute
Sanità
Farmaceutica
Biotecnologia
Industria
Amneal’s BLA Submissions for Two Denosumab Biosimilars Accepted for Review by U.S. FDA
Fonte
Amneal Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
28/02/2025
Biotecnologia
Farmaceutica
Salute
Web e Social Network
Telefonia e Varie
Mercato azionario
Amneal Reports Fourth Quarter and Full Year 2024 Financial Results
Fonte
Amneal Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
19/02/2025
Industria
Biotecnologia
Sanità
Igiene alimentare
Salute
Farmaceutica
Amneal Launches Mesalamine and Receives U.S. FDA Approval for Lenalidomide
Fonte
Amneal Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0